AbCellera Appoints Dr. Victor Sandor to Board

By Greg Peters • Friday, June 05 13:01 • Permanent Link

AbCellera has appointed Dr. Victor Sandor, M.D.C.M., to its board of directors as an independent director.

Sandor brings a record of senior roles in oncology drug development. At Array BioPharma, before the company’s acquisition by Pfizer, he was chief medical officer and helped secure approval of Braftovi and Mektovi. At Incyte, he served as senior vice president for global clinical development and played a key role in the approval of Jakafi. He also served as vice president and chief medical officer for oncology at Biogen and held oncology development roles at AstraZeneca, contributing to the registration of Arimidex and the development of Faslodex.

Sandor currently sits on the boards of ADC Therapeutics, Kymera Therapeutics and Prelude Therapeutics. He also served on the board of Merus before its acquisition by Genmab in 2025.

AbCellera said Sandor’s appointment comes as the company continues advancing its pipeline and translating its antibody discovery platform into clinical outcomes. As a result of these announcements, the company's shares have moved -6.12% on the market, and are now trading at a price of $5.98. For more information, read the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.